Clinical Outcomes
TIA, death, cognitive impairment, stroke, hemorrhage
ADVERSE EVENTS, HEMORRHAGE, TIA, STROKE
At 12 months, adverse events included death (4 of 358 [1.1%]; so below the safety limit), hemorrhage (all systemic; 3 [1.7%] with ISMN vs 1 [0.6%] without ISMN; 3 [1.7%] with cilostazol vs 1 [0.6%] without cilostazol; and 2 [2.2%] with ISMN-cilostazol vs 0 [0%] with no drug), recurrent stroke or TIA (19 [5.3%]), and MI (4 [1.1%]). Functional status was available for 323 participants (90.2%), 47 of whom (14.6%) were dependent. The composite outcome (stroke, TIA, MI, dependence, any cognitive impairment, and death) occurred in 183 of 297 participants (61.6%) with complete data. Cognitive status was available for 307 (tMoCA), 313 (TICS-M), and 319 (verbal fluency) participants, providing a 7-level ordinal cognitive outcome for 308 participants. Of these 308 participants, 184 (59.7%) had mild or worse cognitive impairment. There was no difference in 12-month blood pressure between groups (